CJC-1295 (DAC) Pharmacokinetics
CJC-1295 (DAC) half-life, absorption, routes of administration, and clearance.
Half-Life & Dosing Cadence
CJC-1295 (DAC) has a reported elimination half-life of ~6-8 days. The half-life is the time it takes for blood levels to fall by half, and it's the single biggest driver of how often you dose. That's why the typical schedule lands around 1-2x weekly at 1–2 mg — frequent enough to keep levels in a useful range without stacking up. Shorter half-lives mean more frequent dosing and faster clearance if you stop; longer ones mean steadier levels but a slower washout.
Administration & Absorption
CJC-1295 (DAC) is administered by subcutaneous injection (into the fat layer just under the skin). The primary route is subcutaneous. Subcutaneous delivery is absorbed steadily from the fat depot, giving smoother peaks than intramuscular dosing. Whichever route you use, rotate sites and follow sterile technique.
Reconstitution & Handling
CJC-1295 (DAC) ships as a lyophilized (freeze-dried) powder that you reconstitute before use — a common starting point is a 2 mg vial with 2 mL of bacteriostatic water. Add the water slowly down the vial wall, swirl (don't shake), and let it fully dissolve. Reconstituted peptide is refrigerated and used within its stability window; unmixed powder keeps far longer when stored cold and dark. Always confirm exact dosing math against your own vial and concentration.
Onset & Clearance
Because of its ~6-8 days half-life, CJC-1295 (DAC) reaches steady levels after a few consistent doses and clears the system within roughly four to five half-lives once you stop. Track how you respond over a defined block rather than judging any single dose, and give the compound enough consistent days before deciding whether it's working. This is educational information, not medical advice — review your protocol with a clinician.
Physicochemical and PK profile
- Molecular Formula
- C152H252N44O42
- Molecular Weight
- 3367.89 g/mol
- CAS Number
- 863288-34-0
- Half-Life
- 6-8 days (with DAC); 30 minutes (without DAC)
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl-Lysine)
- Solubility
- Soluble in water and bacteriostatic water
- Storage
- Store lyophilized at -20°C. Reconstituted solution at 2-8°C.
References
- Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 · Teichman SL, et al. · 2006
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006. · Zaidi D, James KA, Wagner GF · 2006
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. · Ionescu M, Frohman LA · 2006
- Substances in Compounding that May Present Significant Safety Risks
- Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009. · Nummenmaa L, Calder AJ · 2009
- The study of doping market: How to produce intelligence from Internet forums. · Pineau T, Schopfer A, Grossrieder L et al. · 2016
- [PDF] December 4, 2024 Pharmacy Compounding Advisory Committee ... · 2024
- Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011. · Chiaretti A, Ruggiero A, Barbi E, Pierri F, Maurizi P, Fantacci C, Bersani G, Riccardi R · 2011